C
일양약품
007570KOSPI47.5 / 100
Reference Date: 2026-10-23
Financial Score21.0 / 40
News Sentiment12.5 / 25
Momentum7.0 / 20
Disclosure7.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but Operating Profit is on a declining trend. Plunged 15.5% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
Ilwang Pharm focuses on developing innovative drugs like 'Noltek' (ulcer treatment) and 'Sufekt' (leukemia treatment), expanding into global markets, and strengthening long-term growth through R&D investments. In 2022, the company reported consolidated sales of 2.724 trillion KRW and operating profit of 49 billion KRW, with ongoing market expansion in China and Mexico.
Number of Employees
665people
Average Salary
84.3M KRW
Score Calculation Basis
Detailed Financial Score
PER
18.56Industry Average 15.003.0Point
Higher than industry avg (caution)
PBR
0.55Industry Average 1.207.0Point
Half of industry avg (excellent)
ROE
2.97Industry Average 8.001.0Point
Well below industry avg
Debt Ratio
18.54Industry Average 100.008.0Point
Half of industry avg (excellent)
Trend 2023~20252.0 / 10 points
Revenue Growth Rate
1.0 / 3
Avg ▲0.3% (2-year basis)
Operating Profit Growth Rate
0.0 / 3
Avg ▼43.9% (2-year basis)
ROE Trend
1.0 / 4
Avg ROE 2.2% (improving, 3yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position1.0Point
Near 52w low (0%, downtrend)
Current 6,960Won52-week high 13,63052-week low 6,960
1-month return0.0Point
1m -15.53% (strong drop)
Volume trend6.0Point
Volume increasing
Detailed Disclosure
1 totalPositive 0Neutral 0Negative 1
- Negative[기재정정]불성실공시법인지정2026-10-08